UNSPSC 51173209: Bisacodyl/magnesium citrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.

UNSPSC 51173209 Bisacodyl/magnesium citrate is a Commodity code that in recent state and local procurement activity represents drug testing and specimen collection services rather than pharmaceutical products. Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services — the only recent opportunity tagged to this code — solicits staffing, lab operations, and testing methodologies including immunoassay screening with LC/MS/MS or GC/MS confirmation, oral fluid and hair testing, and electronic result reporting. The county estimates approximately 25,031 annual tests across five-panel and six-panel screens and ancillary testing, with pricing submitted on a per-test basis under three service models: screening only, confirmation after screening, and screening with automatic confirmation of positives. The issuing body is a county criminal-justice supervision agency funded through state appropriations, indicating that recent activity under this code reflects demand from criminal-justice and corrections departments rather than healthcare procurement offices.

The code shows activity concentrated in Texas, with Collin County's solicitation representing the primary recent opportunity. Collin County Community Supervision and Corrections Department issued RFP 2026-327 with proposals due July 23, 2026, at 2:00 p.m., seeking a vendor or multiple vendors to operate collection sites in Plano and McKinney with staffing, lab certification from SAMHSA, TX DPS, or CAP, and a two-year initial contract term with optional renewals not to exceed five years total. The estimated contract value is $600,000. Evaluation weights vendor understanding (30 points), firm qualifications (25 points), client references (15 points), cost (30 points), and optional demonstrations and interviews (up to 30 points). The anticipated award date is August 10, 2026. The mismatch between the code's nominal pharmaceutical scope and the criminal-justice testing services being solicited suggests this code may not be the primary driver for pharmaceutical procurement in state and local markets.